Company Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).
It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.
In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy.
The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | George Magrath |
Contact Details
Address: 8 Davis Drive, Suite 220 Durham, North Carolina 27709 United States | |
| Phone | 984 884 6030 |
| Website | opusgtx.com |
Stock Details
| Ticker Symbol | IRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001228627 |
| ISIN Number | US67577R1023 |
| Employer ID | 11-3516358 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George Magrath M.B.A., M.D., M.S. | Chief Executive Officer and Director |
| Dr. Benjamin R. Yerxa Ph.D. | President and Director |
| Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific and Development Officer |
| Joseph K. Schachle MBA | Chief Operating Officer |
| Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development and Secretary |
| Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance |
| Bindu Manne | Head of Market Development and Commercialization |
| Erik Sims | Director and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 6, 2025 | SCHEDULE 13D/A | Filing |
| May 1, 2025 | 8-K | Current Report |
| Apr 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2025 | EFFECT | Notice of Effectiveness |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |